# Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor

> **NCT02246127** · PHASE3 · COMPLETED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 141 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Drug: Everolimus
- **DRUG:** STZ-5FU

## Key facts

- **NCT ID:** NCT02246127
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-27
- **Primary completion:** 2020-11-18
- **Final completion:** 2021-07-12
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246127, "Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02246127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*